Novo Nordisk says Ozempic a “very likely” target in next Medicare drug pricing talks

hapabapa/iStock Editorial via Getty Images A top executive at Novo Nordisk ( NVO ) warned Tuesday that the company’s diabetes therapy Ozempic will likely be selected for the next round of Medicare drug pricing negotiations, which aim to seek discounts for blockbuster meds supplied to the federal.